Details:
Under this agreement, Kirk M. Druey, M.D., and colleagues at the NIAID will investigate PMC-403 in preclinical models. PharmAbcine will discuss potential clinical development in collaboration with the NIH as the study progresses.
Lead Product(s): PMC-403
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PMC-403
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: NIH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 18, 2020